Wilson Therapeutics Appoints Anders Martin-Lof as Chief Financial Officer

Nov 03, 2015, 05:00 ET from Wilson Therapeutics

STOCKHOLM, Nov. 3, 2015 /PRNewswire/ -- Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced the appointment of Anders Martin-Lof as Chief Financial Officer (CFO). Mr. Martin-Lof will report to CEO Jonas Hansson, and will join the company's management team.

"We are pleased to welcome Anders to the team," said Jonas Hansson. "His leadership experience and extensive expertise within the life sciences industry will be tremendous helpful to Wilson as we continue our path forward and pursue our goal to bring new treatments to patients with Wilson's Disease."

Mr. Martin-Lof has more than 15 years' experience in the life science sector and has held a number of management positions in finance, investor relations and business development. Most recently, he served as CFO of Extenda, a privately-held software company.  Before joining Extenda, he was the CFO of RaySearch Laboratories AB, a medical technology company that develops advanced software solutions for radiation therapy of cancer.

Prior to joining RaySearch, Mr. Martin-Lof served as Director of Investor Relations and held various business development positions for the biotech company Biovitrum (SOBI). Before that, he was a management consultant at the Boston Consulting Group, Cell Network and co-founder and CEO of ScienceCap, a consulting firm focused on small-cap companies in the biotech and medtech sectors.

Anders Martin-Lof holds a M.Sc. in Engineering Physics from the Royal Institute of Technology and a B.Sc in Business Administration and Economics from Stockholm University.

About Wilson's Disease

Wilson's Disease is a rare autosomal recessive disorder caused by mutations in the ATP7B gene, resulting in deficient production of the copper-transporter ATPase-2. Deficient or absent production of ATPase-2 leads to impaired incorporation of Cu into ceruloplasmin and impairment of biliary Cu excretion, which allows copper to accumulate in the body. The build-up of copper in liver, brain, kidneys and other tissues of Wilson's Disease patients produces significant organ damage and dysfunction. Untreated or inadequately treated Wilson's Disease can result in brain damage, liver failure and death. The overall prevalence of Wilson's Disease is estimated to be 1-2 in 30,000 individuals.

About Wilson Therapeutics

Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson's Disease through the development of new treatment options and increased awareness and education. The Company's lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson's Disease. Investors include Abingworth, HealthCap, MVM Life Science Partners and NeoMed.

Contact:
Wilson Therapeutics
Jonas Hansson
CEO
Tel: +46709441877
www.wilsontherapeutics.com

Ami Knoefler
Spark BioComm LLC
Tel: + 1 650 739 9952

 

SOURCE Wilson Therapeutics



RELATED LINKS

http://www.wilsontherapeutics.com